Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

AbbVie and Disco strike deal worth up to $2.54B for solid tumor targets

EndpointsView source article

Part of story

AbbVie strikes deal worth up to $2.54B with Disco Pharmaceuticals for cancer therapies

AbbVie agreed to pay up to $2.54 billion to develop antibody-drug conjugate and T cell engager cancer treatments with Disco Pharmaceuticals, a preclinical German biotech. The deal expands AbbVie's oncology pipeline targeting solid tumors.

Nov 19, 2026·2 sourcesCancer treatmentTargeted cancer therapyDrug developmentCancer & OncologyCancer and Cancer TreatmentPharmaceutical IndustryBiotech innovation
AbbVie strikes deal worth up to $2.54B with Disco Pharmaceuticals for cancer therapies
00

Other sources for this story

Reuters

AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco | Reuters